These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 35363262)

  • 1. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
    Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
    Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.
    Seppälä TT; Zimmerman JW; Sereni E; Plenker D; Suri R; Rozich N; Blair A; Thomas DL; Teinor J; Javed A; Patel H; Cameron JL; Burns WR; He J; Tuveson DA; Jaffee EM; Eshleman J; Szabolcs A; Ryan DP; Ting DT; Wolfgang CL; Burkhart RA
    Ann Surg; 2020 Sep; 272(3):427-435. PubMed ID: 32657929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
    Zhang Y; Houchen CW; Li M
    Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
    Hennig A; Baenke F; Klimova A; Drukewitz S; Jahnke B; Brückmann S; Secci R; Winter C; Schmäche T; Seidlitz T; Bereuter JP; Polster H; Eckhardt L; Schneider SA; Brückner S; Schmelz R; Babatz J; Kahlert C; Distler M; Hampe J; Reichert M; Zeißig S; Folprecht G; Weitz J; Aust D; Welsch T; Stange DE
    J Pathol; 2022 Aug; 257(5):607-619. PubMed ID: 35373359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinical application in pancreatic ductal adenocarcinoma (with video).
    Kim H; Jang J; Choi JH; Song JH; Lee SH; Park J; Ryoo SK; Lee EM; Jeong HO; Kim S; Lee SH; Lee KH; Lee KT; Kim KM; Jang KT; Lee H; Lee S; Lee JK; Park JK
    Gastrointest Endosc; 2024 Jul; 100(1):85-96.e9. PubMed ID: 38447660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.
    Kang Y; Deng J; Ling J; Li X; Chiang YJ; Koay EJ; Wang H; Burks JK; Chiao PJ; Hurd MW; Bhutani MS; Lee JH; Weston BR; Maitra A; Ikoma N; Tzeng CD; Lee JE; DePinho RA; Wolff RA; Pant S; McAllister F; Katz MH; Fleming JB; Kim MP
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36282600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
    Grossman JE; Muthuswamy L; Huang L; Akshinthala D; Perea S; Gonzalez RS; Tsai LL; Cohen J; Bockorny B; Bullock AJ; Schlechter B; Peters MLB; Conahan C; Narasimhan S; Lim C; Davis RB; Besaw R; Sawhney MS; Pleskow D; Berzin TM; Smith M; Kent TS; Callery M; Muthuswamy SK; Hidalgo M
    Clin Cancer Res; 2022 Feb; 28(4):708-718. PubMed ID: 34789479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction.
    Matsumoto K; Fujimori N; Ichihara K; Takeno A; Murakami M; Ohno A; Kakehashi S; Teramatsu K; Ueda K; Nakata K; Sugahara O; Yamamoto T; Matsumoto A; Nakayama KI; Oda Y; Nakamura M; Ogawa Y
    J Gastroenterol; 2024 Jul; 59(7):629-640. PubMed ID: 38684511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
    Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
    EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy.
    Choi D; Gonzalez-Suarez AM; Dumbrava MG; Medlyn M; de Hoyos-Vega JM; Cichocki F; Miller JS; Ding L; Zhu M; Stybayeva G; Gaspar-Maia A; Billadeau DD; Ma WW; Revzin A
    Adv Sci (Weinh); 2024 Feb; 11(5):e2303088. PubMed ID: 38018486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy.
    van Eijck CWF; Sabroso-Lasa S; Strijk GJ; Mustafa DAM; Fellah A; Koerkamp BG; Malats N; van Eijck CHJ
    Neoplasia; 2024 Mar; 49():100975. PubMed ID: 38335839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids.
    Lumibao JC; Okhovat SR; Peck KL; Lin X; Lande K; Yomtoubian S; Ng I; Tiriac H; Lowy AM; Zou J; Engle DD
    JCI Insight; 2024 Jan; 9(1):. PubMed ID: 38051586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
    Farshadi EA; Chang J; Sampadi B; Doukas M; Van 't Land F; van der Sijde F; Vietsch EE; Pothof J; Koerkamp BG; van Eijck CHJ
    Clin Cancer Res; 2021 Dec; 27(23):6602-6612. PubMed ID: 34580113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
    Tiriac H; Belleau P; Engle DD; Plenker D; Deschênes A; Somerville TDD; Froeling FEM; Burkhart RA; Denroche RE; Jang GH; Miyabayashi K; Young CM; Patel H; Ma M; LaComb JF; Palmaira RLD; Javed AA; Huynh JC; Johnson M; Arora K; Robine N; Shah M; Sanghvi R; Goetz AB; Lowder CY; Martello L; Driehuis E; LeComte N; Askan G; Iacobuzio-Donahue CA; Clevers H; Wood LD; Hruban RH; Thompson E; Aguirre AJ; Wolpin BM; Sasson A; Kim J; Wu M; Bucobo JC; Allen P; Sejpal DV; Nealon W; Sullivan JD; Winter JM; Gimotty PA; Grem JL; DiMaio DJ; Buscaglia JM; Grandgenett PM; Brody JR; Hollingsworth MA; O'Kane GM; Notta F; Kim E; Crawford JM; Devoe C; Ocean A; Wolfgang CL; Yu KH; Li E; Vakoc CR; Hubert B; Fischer SE; Wilson JM; Moffitt R; Knox J; Krasnitz A; Gallinger S; Tuveson DA
    Cancer Discov; 2018 Sep; 8(9):1112-1129. PubMed ID: 29853643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy.
    Demyan L; Habowski AN; Plenker D; King DA; Standring OJ; Tsang C; St Surin L; Rishi A; Crawford JM; Boyd J; Pasha SA; Patel H; Galluzzo Z; Metz C; Gregersen PK; Fox S; Valente C; Abadali S; Matadial-Ragoo S; DePeralta DK; Deutsch GB; Herman JM; Talamini MA; Tuveson DA; Weiss MJ
    Ann Surg; 2022 Sep; 276(3):450-462. PubMed ID: 35972511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
    Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
    Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
    van Eijck CWF; de Koning W; van der Sijde F; Moskie M; Groot Koerkamp B; Homs MYV; van der Burg SH; van Eijck CHJ; Mustafa DAM
    Eur J Cancer; 2023 Mar; 181():119-134. PubMed ID: 36652890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.